The E1B19K-deleted Oncolytic Adenovirus Mutant AdΔ19K Sensitizes Pancreatic Cancer Cells to Drug-induced DNA-damage by Down-regulating Claspin and Mre11

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Feb 13

PMID 26872382

Citations 14

Authors

Constantia Pantelidou

Gioia Cherubini

Nick R Lemoine

Gunnel Hallden

Affiliations

Soon will be listed here.

Abstract

Adenovirus-mediated sensitization of cancer cells to cytotoxic drugs depends on simultaneous interactions of early viral genes with cell death and survival pathways. It is unclear what cellular factors mediate these interactions in the presence of DNA-damaging drugs. We found that adenovirus prevents Chk1-mediated checkpoint activation through inactivation of Mre11 and downregulation of the pChk1 adaptor-protein, Claspin, in cells with high levels of DNA-damage induced by the cytotoxic drugs gemcitabine and irinotecan. The mechanisms for Claspin downregulation involve decreased transcription and increased degradation, further attenuating pChk1-mediated signalling. Live cell imaging demonstrated that low doses of gemcitabine caused multiple mitotic aberrations including multipolar spindles, micro- and multi-nucleation and cytokinesis failure. A mutant virus with the anti-apoptotic E1B19K-gene deleted (AdΔ19K) further enhanced cell killing, Claspin downregulation, and potentiated drug-induced DNA damage and mitotic aberrations. Decreased Claspin expression and inactivation of Mre11 contributed to the enhanced cell killing in combination with DNA-damaging drugs. These results reveal novel mechanisms that are utilised by adenovirus to ensure completion of its life cycle in the presence of cellular DNA damage. Taken together, our findings reveal novel cellular targets that may be exploited when developing improved anti-cancer therapeutics.

Citing Articles

Single-molecule characterization of SV40 replisome and novel factors: human FPC and Mcm10.

Ouyang Y, Al-Amodi A, Tehseen M, Alhudhali L, Shirbini A, Takahashi M Nucleic Acids Res. 2024; 52(15):8880-8896.

PMID: 38967018 PMC: 11347169. DOI: 10.1093/nar/gkae565.

Inhibition of Bromodomain Proteins Enhances Oncolytic HAdVC5 Replication and Efficacy in Pancreatic Ductal Adenocarcinoma (PDAC) Models.

Miao T, Symonds A, Hickman O, Wu D, Wang P, Lemoine N Int J Mol Sci. 2024; 25(2).

PMID: 38279262 PMC: 10816486. DOI: 10.3390/ijms25021265.

Complexing the Oncolytic Adenoviruses Ad∆∆ and Ad-3∆-A20T with Cationic Nanoparticles Enhances Viral Infection and Spread in Prostate and Pancreatic Cancer Models.

Man Y, Aguirre-Hernandez C, Fernandez A, Martin-Duque P, Gonzalez-Pastor R, Hallden G Int J Mol Sci. 2022; 23(16).

PMID: 36012152 PMC: 9408166. DOI: 10.3390/ijms23168884.

HDAC Inhibitors Enhance Efficacy of the Oncolytic Adenoviruses Ad∆∆ and Ad-3∆-A20T in Pancreatic and Triple-Negative Breast Cancer Models.

Rodriguez M, Rodriguez I, Nattress C, Qureshi A, Hallden G Viruses. 2022; 14(5).

PMID: 35632748 PMC: 9143155. DOI: 10.3390/v14051006.

Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions.

Lu S, Hua J, Xu J, Wei M, Liang C, Meng Q Int J Biol Sci. 2021; 17(10):2666-2682.

PMID: 34326701 PMC: 8315022. DOI: 10.7150/ijbs.59117.

References

Sorensen C, Hansen L, Dziegielewski J, Syljuasen R, Lundin C, Bartek J . The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol. 2005; 7(2):195-201. DOI: 10.1038/ncb1212. View

Woo J, Berk A . Adenovirus ubiquitin-protein ligase stimulates viral late mRNA nuclear export. J Virol. 2006; 81(2):575-87. PMC: 1797459. DOI: 10.1128/JVI.01725-06. View

Miranda E, Maya Pineda H, Oberg D, Cherubini G, Garate Z, Lemoine N . Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region. PLoS One. 2012; 7(10):e46617. PMC: 3463540. DOI: 10.1371/journal.pone.0046617. View

Leitner S, Sweeney K, Oberg D, Davies D, Miranda E, Lemoine N . Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo. Clin Cancer Res. 2009; 15(5):1730-40. PMC: 2873675. DOI: 10.1158/1078-0432.CCR-08-2008. View

Li S, Brignole C, Marcellus R, Thirlwell S, Binda O, McQuoid M . The adenovirus E4orf4 protein induces G2/M arrest and cell death by blocking protein phosphatase 2A activity regulated by the B55 subunit. J Virol. 2009; 83(17):8340-52. PMC: 2738146. DOI: 10.1128/JVI.00711-09. View

Liu T, Wang Y, Hallden G, Brooks G, Francis J, Lemoine N . Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus. Gene Ther. 2005; 12(17):1333-46. DOI: 10.1038/sj.gt.3302555. View

Onimaru M, Ohuchida K, Nagai E, Mizumoto K, Egami T, Cui L . Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer. Cancer Lett. 2010; 294(2):178-86. DOI: 10.1016/j.canlet.2010.01.034. View

Freytag S, Stricker H, Movsas B, Kim J . Prostate cancer gene therapy clinical trials. Mol Ther. 2007; 15(6):1042-52. DOI: 10.1038/sj.mt.6300162. View

Chini C, Chen J . Claspin, a regulator of Chk1 in DNA replication stress pathway. DNA Repair (Amst). 2004; 3(8-9):1033-7. DOI: 10.1016/j.dnarep.2004.03.001. View

10.

Lee W, Tai D, Tsai S, Yeh C, Chao Y, Lee S . Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine. Cancer Res. 2003; 63(19):6229-36. View

11.

Russell W . Adenoviruses: update on structure and function. J Gen Virol. 2008; 90(Pt 1):1-20. DOI: 10.1099/vir.0.003087-0. View

12.

De Luca A, Mangiacasale R, Severino A, Malquori L, Baldi A, Palena A . E1A deregulates the centrosome cycle in a Ran GTPase-dependent manner. Cancer Res. 2003; 63(6):1430-7. View

13.

Moore P, Sipos B, Orlandini S, Sorio C, Real F, Lemoine N . Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch. 2002; 439(6):798-802. DOI: 10.1007/s004280100474. View

14.

White E . Mechanisms of apoptosis regulation by viral oncogenes in infection and tumorigenesis. Cell Death Differ. 2006; 13(8):1371-7. DOI: 10.1038/sj.cdd.4401941. View

15.

Cherubini G, Kallin C, Mozetic A, Hammaren-Busch K, Muller H, Lemoine N . The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models. Gene Ther. 2011; 18(12):1157-65. DOI: 10.1038/gt.2011.141. View

16.

Oberg D, Yanover E, Adam V, Sweeney K, Costas C, Lemoine N . Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers. Clin Cancer Res. 2010; 16(2):541-53. PMC: 2825678. DOI: 10.1158/1078-0432.CCR-09-1960. View

17.

Chini C, Chen J . Human claspin is required for replication checkpoint control. J Biol Chem. 2003; 278(32):30057-62. DOI: 10.1074/jbc.M301136200. View

18.

Patel M, Kratzke R . Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res. 2013; 161(4):355-64. DOI: 10.1016/j.trsl.2012.12.010. View

19.

Liu D, Kojima T, Ouchi M, Kuroda S, Watanabe Y, Hashimoto Y . Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol Cancer Ther. 2009; 8(4):980-7. DOI: 10.1158/1535-7163.MCT-08-0901. View

20.

Wang H, Liu Z, Wang Z, Li F, Zhao Y, Chen G . [Double-mutated oncolytic adenovirus combined with gemcitabine for treating an orthotopic nude mouse model of bladder cancer]. Zhonghua Zhong Liu Za Zhi. 2013; 35(6):412-7. View